SP600125 Liposomes, Formulation HZ12
PEGylated liposomes containing JNK inhibitor SP600125 (Nsc75890). SP600125 is a reversible, ATP-competitive broad-spectrum JNK inhibitor (JNK1/JNK2, IC50 40 nM; JNK3, IC50 90 nM). with IC50s of 40, 40 and 90 nM for JNK1, JNK2 and JNK3, respectively. SP600125 is also a broad‐spectrum inhibitor of serine/threonine kinases including Aurora kinase A，FLT3 and TRKA. SP600125 inhibits ferroptosis, autophagy, and activates apoptosis. SP600125 is insoluble in aqueous media. This product is a pre-formulated liposomal version of Sp600125 which is supplied ready to use in vitro or in vivo. The liposomes are PEGylated for optimal in vivo performance. For preclinical research use only.
We synthesize custom liposomes like this. To see a full list of our formulation capabilities, click here.
Figure 1 (Thumbnail). Solubilization of SP600125 by liposomes. SP600125 is shown under magnification in free or liposomal forms at 250 mcg/mL. Left: SP600125 is insoluble in aqueous media. SP600125 was dissolved in DMSO and diluted in 322 Buffer (292 mM sucrose, 0.5% DPBS) to examine aqueous solubility. Right: Matched concentration of SP600125 is shown in liposomal form (formulation HZ12) in the same bulk solution.
Figure 2. DLS analysis of SP600125 Liposomes, Formulation HZ12 (batch 89147). The average size and PDI of triplicate measurements are annotated on the representative snapshot from DLS data acquisition screen. The data are representative of a typical batch.
PEGylated liposomes loaded with SP600125 (Nsc75890)
|Concentration Total Lipid||60 mM|
|Concentration Cefixime||250 mcg/mL|
|Hydration Solution||292 mM sucrose, 0.5% DPBS (1X)|
|External Solution||292 mM sucrose, 0.5% DPBS (1X)|
|Liposome Avg. Size||70-120 nm|
Bioactive Compound Details
|Alias(es)||SP 600125; Nsc75890; JNK Inhibitor II|
|Target(s)||JNK1, JNK2, JNK3|
|Signaling Pathway||JNK pathway|
|2 °C to 8 °C (do not freeze), protect from light|
|Shelf Life*||At least 1 month|
*Product is too new for long-term stability data. This section will be updated regularly as new data becomes available.